logo

For the Inventor, By the Inventor

Pembroke, Bermuda

Celgene Car LLC


USPTO Granted Patents = 44

% Expired Patents = 6.8



Forward Citations = 237

Loading Chart...
Loading Chart...

53 inventors (with patents filed for the assignee):

goldMedal Deqiang Niu (29 out of 83 patents)

silverMedal Juswinder Singh (28 out of 68 patents)

bronzeMedal Russell Colyn Petter (28 out of 82 patents)

4.  Lixin Qiao (13 out of 40 patents)

5.  Joseph John McDonald (12 out of 14 patents)

6.  Zhendong Zhu (12 out of 20 patents)

7.  Hormoz Mazdiyasni (11 out of 19 patents)

8.  Kwangho Lee (10 out of 28 patents)

9.  Richland Wayne Tester (9 out of 30 patents)

10.  John Malona (9 out of 11 patents)

11.  Arthur F Kluge (8 out of 96 patents)

12.  Alexander L Ruchelman (6 out of 56 patents)

13.  William Frederick Westlin, Iii (6 out of 15 patents)

14.  Yike Ni (6 out of 7 patents)

15.  Chittari Pabba (6 out of 8 patents)


Core Competencies:
MK2 Inhibitors
ERK Inhibitors
Heteroaryl Compounds
Pyrimidine Derivatives
Protein Kinase
Covalent Modification
EGFR Inhibitors
HCV Protease Inhibitors
Solid Forms
Deuterated Analogs
Ligand-Directed
Substituted Compounds

44 patents:

1. 11655257 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2023-05-23),
2. 11629153 - Forms and compositions of a MK2 inhibitor (2023-04-18),
3. 11584757 - MK2 inhibitors and uses thereof (2023-02-21),
4. 11542492 - Ligand-directed covalent modification of protein (2023-01-03),
5. 11351168 - 2,4-disubstituted pyrimidines useful as kinase inhibitors (2022-06-07),
6. 11292772 - Salts of an epidermal growth factor receptor kinase inhibitor (2022-04-05),
7. 11230551 - Deuterated analogs of MK2 inhibitors and uses thereof (2022-01-25),
8. 11124525 - Heteroaryl compounds useful as MK2 inhibitors (2021-09-21),
9. 11098061 - MK2 inhibitors and uses thereof (2021-08-24),
10. 11098057 - 9,10,11,12-tetrahydro-8H-[1,4]diazepino[5',6′:4,5]thieno[3,2-F]quinolin-8-one compounds and uses thereof (2021-08-24),
11. 11096942 - Heterocyclic compounds and uses thereof (2021-08-24),
12. 10946016 - Solid forms of an epidermal growth factor receptor kinase inhibitor (2021-03-16),
13. 10894796 - MK2 inhibitors, synthesis thereof, and intermediates thereto (2021-01-19),
14. 10882867 - Forms and compositions of a MK2 inhibitor (2021-01-05),
15. 10828300 - Substituted 2,4-diaminopyrimidines as kinase inhibitors (2020-11-10),
Celgene Car LLC, based in Pembroke, specializes in the development of innovative therapeutic solutions targeting various protein kinases. The company focuses on advanced research in MK2 inhibitors, EGFR kinase inhibitors, and ERK inhibitors, among other areas. By leveraging heteroaryl compounds and pyrimidines, Celgene Car aims to create novel treatments that utilize covalent modification and deuterated analogs, contributing to the evolving landscape of targeted therapies in oncology and related fields.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Celgene Car LLC
44 Patents

#1 in Pembroke

#18 in Bermuda

#15,727 in the World

Pembroke, BM
Pembroke, Bermuda

Celgene Car LLC

Forward Citations = 237

53 inventors:

goldMedal Deqiang Niu (29 out of 83 patents)

silverMedal Juswinder Singh (28 out of 68 patents)

bronzeMedal Russell Colyn Petter (28 out of 82 patents)

4.  Lixin Qiao (13 out of 40 patents)

5.  Joseph John McDonald (12 out of 14 patents)

Please report any incorrect information to [email protected]
Loading…